- This topic has 4 replies, 5 voices, and was last updated 8 years, 7 months ago by
.
-
Posts
-
Interested In hearing from someone who may have knowledge of a clinical trial involving immunotherapy as second line treatment for urothelial carcinoma. Toronto area.
Thankshttp://forum.bladdercancercanada.org/en/facing-bladder-cancer/clinical-trials/
I believe Sunnybrook hospital has an immunotheray trial for Muscle Invasive Bladder Cancer.
Another source for information is Roche Canada in Mississauga.
Hoffmann-La Roche Limited
7070 Mississauga Road
Mississauga, ON L5N 5M8
Tel.: 1-800-561-1759
http://roche-trials.com/searchFullText.action?criteriaTextInResults=&selectedProduct=–+All+–&selectedCondition=Bladder+Cancer&selectedCountry=Canada&category=–+All+–&pageSize=50&matchAnyWord=true&currPage=1&pageCountReq=5&drug=2
Good luck,
JackThere is a Canadian database of studies at:
http://www.hc-sc.gc.ca/dhp-mps/prodpharma/databasdonclinThere is a worldwide database at:
https://clinicaltrials.gov/ct2/search/indexYour oncologist will be aware of anything going on in your area.
Check out Princess Margaret Hospital Tumour Immunotherapy Program, which has multiple immunotherapy trials, checkpoint inhibitor drugs, as well as T-Cell therapies; one of the few sites worldwide and in Canada with so much available.
Good luck!(Dr. Marcus Butler and Dr. Lillian Siu)
I’m currently about a third of the way through an immunotherapy drug trial at Sunnybrook. However, it is post-cystectomy with neo. My Stage 3 (aggressive) cancer had luckily not spread and lymph nodes etc were clean. I’d had a radical hysterectomy in 2002, so perhaps that helped it not to spread. Anyway, I think the trials is looking to see if the drug (they use IMvigor now; it started out being called Tecentriq) has any effect on recurrence. The oncologist who is in charge of my trial is Dr. Susanna Cheng (she’s wonderful). Her clinical trials nurse is Nesan Bandali (she’s also wonderful). They may be able to point you in the right direction.
- You must be logged in to reply to this topic.
